Johan Giléus
Johan Giléus
Acting Chief Executive Officer (CEO). Chief Financial Officer (CFO) since 2017. Board member of InDex Pharmaceuticals AB and InDex Diagnostics AB.
Read more
Johan Giléus
Johan Giléus
Acting Chief Executive Officer (CEO). Chief Financial Officer (CFO) since 2017. Board member of InDex Pharmaceuticals AB and InDex Diagnostics AB.

Born: 1965.

Other current assignments: Giléus is a member of the board and CEO of Giléus Consulting AB and Giléus Invest AB. Giléus is also partner of Professionell ägarstyrning i Sverige AB.

Experience: Giléus is also engaged as an independent financial advisor with M&A, external financial reporting and other stock market issues. He has broad experience from sectors like Life Science, Energy, Services and Manufacturing. During the last 25 years Giléus has worked with Swedish and international strategic and financial clients in acquisitions and divestments. Giléus was until May 2015 partner at Deloitte AB with a focus on M&A and stock market issues. Giléus was also on the board of Deloitte AB up until 2014. He has also been involved in some 75 IPOs. Giléus has studied business administration at Stockholm University.

Shareholding in InDex: Direct holding of 240 000 shares and 133 333 warrants (LTIP 2020) and 772 300 employee stock options (LTIP 2021) and 772 300 stock options (LTIP 2022).

Dr. Eva Arlander
Dr. Eva Arlander
Chief Development Officer (CDO) since May 2022
Read more
Dr. Eva Arlander
Dr. Eva Arlander
Chief Development Officer (CDO) since May 2022

Born: 1964

Other current assignments: –

Experience: Eva Arlander has extensive experience from the pharmaceutical industry and has held senior positions at for example Astra Zeneca, Medivir and Affibody with a main focus on clinical development. She has also been department head at the Medical Products Agency. She is a pharmacist and holds a PhD in clinical pharmacology from the Karolinska Institutet.

Shareholding in InDex: Direct holding of 772 300 employee stock option (LTIP 2022).

Dr. Anders Bröijersén
Dr. Anders Bröijersén
Chief Medical Officer (CMO) since May 2022
Read more
Dr. Anders Bröijersén
Dr. Anders Bröijersén
Chief Medical Officer (CMO) since May 2022

Born: 1964

Other current assignments: –

Experience: Anders Bröijersén has 15 years of experience in Clinical Development, Medical Affairs and Drug Safety at leading pharmaceutical companies such as Boehringer Ingelheim, MSD and Sobi. He is a medical doctor with a specialist training in internal medicine and holds a PhD from the Karolinska Institutet.

Shareholding in InDex: Direct holding of 338 000 employee stock options (LTIP 2021) and 772 300 employee stock option (LTIP 2022).

Dr. Charlotte Admyre
Dr. Charlotte Admyre
Chief Scientific Officer (CSO) since May 2022
Read more
Dr. Charlotte Admyre
Dr. Charlotte Admyre
Chief Scientific Officer (CSO) since May 2022

Born: 1979

Other current assignments:

Experience: Admyre has more than 14 years of experience from the pharmaceutical industry and has held several key positions within research and development, business development and investor relations. She holds a PhD in Immunology and a Master of Biomedicine from the Karolinska Institutet.

Shareholding in InDex: Direct holding of 9 036 shares and 58 333 warrants (LTIP 2020) and 338 000 employee stock options (LTIP 2021) and 772 300 employee stock option (LTIP 2022).